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Efficient T-cell targeting, infiltration and activation within tumors is crucial for successful
adoptive T-cell therapy. Intravital microscopy is a powerful tool for the visualization of
T-cell behavior within tumors, as well as spatial and temporal heterogeneity in response
to immunotherapy. Here we describe an experimental approach for intravital imaging
of adoptive T-cell morphology, mobility and trafficking in a skin-flap tumor model,
following immune modulation with immune checkpoint inhibitors (ICIs) targeting PD-L1
and CTLA-4. A syngeneic model of ovalbumin and mCherry-expressing amelanotic
mouse melanoma was used in conjunction with adoptively transferred OT-1+ cytotoxic
T-cells expressing GFP to image antigen-specific live T-cell behavior within the tumor
microenvironment. Dynamic image analysis of T-cell motility showed distinct CD8+
T-cell migration patterns and morpho-dynamics within different tumor compartments in
response to ICIs: this approach was used to cluster T-cell behavior into four groups
based on velocity and meandering index. The results showed that most T-cells within
the tumor periphery demonstrated Lévy-like trajectories, consistent with tumor cell
searching strategies. T-cells adjacent to tumor cells had reduced velocity and appeared to
probe the local environment, consistent with cell-cell interactions. An increased number
of T-cells were detected following treatment, traveling at lower mean velocities than
controls, and demonstrating reduced displacement consistent with target engagement.
Histogram-based analysis of immunofluorescent images from harvested tumors showed
that in the ICI-treated mice there was a higher density of CD31+ vessels compared to
untreated controls and a greater infiltration of T-cells towards the tumor core, consistent
with increased cellular trafficking post-treatment.
Keywords: intravital imaging, adoptive T-cell therapy, immune checkpoint inhibitors, immunocompetent,
melanoma
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INTRODUCTION
Adoptive T-cell therapy (ATC) is emerging as a promising
approach for the treatment of solid cancers (1, 2). Tumor-
infiltrating lymphocytes (TIL) and chimeric antigen receptor
(CAR) T-cells are currently undergoing Phase I/II clinical trials
for treatment of solid malignancies (2, 3). However, ATC
presents significant challenges for routine clinical use due to
variable patient response to therapy and the requirement for
a high specificity to tumor-associated antigens (4, 5). T-cell
infiltration into normal tissues after systemic administration
raises the possibility for off-target and dose-limiting toxicities
(4–6). Furthermore, T-cell trafficking and infiltration into solid
tumors is limited by physical barriers such as the stromal network
and extracellular matrix surrounding the tumor cells. Regional
delivery of T-cells via intratumoral injection has been proposed
as a more targeted method to overcome these physical barriers,
but remains technically challenging as not all tumors are easily
accessible and it is difficult to reproducibly distribute the injected
cells within the tumor (7, 8).
In addition, the efficacy of ATC is limited by hostile
microenvironmental factors such as hypoxia and metabolite
depletion caused by rapidly growing tumors, the presence
of immunosuppressive cell types such as cancer-associated
fibroblasts, regulatory T-cells, and myeloid-derived suppressor
cells, many of which express ligands for immune checkpoint
receptors. Synergistic combination of ATC with other targeted
therapies to alter the tumor microenvironment may overcome
these limitations (9–11).
Monoclonal antibodies targeting the cytotoxic T-lymphocyte
antigen-4 (CTLA-4) and programmed cell death 1 (PD-
1/PD-L1) checkpoint pathways are used in the clinic to
treat several solid tumors such as metastatic melanoma and
non-small cell lung carcinoma (12–16). Immune checkpoint
inhibitors may improve the efficacy of ATC by releasing
constitutive inhibition on T-cell function through depletion
of subpopulations of immunosuppressive cells within the
tumor microenvironment via Fc-mediated antibody-dependent
cellular cytotoxicity (ADCC) mechanisms (17). Several recent
clinical trials have demonstrated the safety and efficacy of
combining ATC with CTLA-4 and PD-1/PDL1 targeting
strategies: for example, using anti-PD-1 as an immune booster
after intrapleural CAR T-cell administration in patients with
mesothelin-positive malignant pleural disease (18), novel third-
generation CAR T-cells with the capability for expressing
and secreting CTLA-4 and PD-1 antibodies into the tumor
microenvironment (19), and CRISPR/Cas9 PD-1 knockout
CAR T-cells (20). Many of these ATC methods utilize prior
lymphodepletion to reset the regulatory components of the
immune system and promote the engraftment and long-term
persistence of transferred T-cells. Whilst this enhances the anti-
tumor efficacy of transferred T-cells, it is potentially toxic for
patients (21, 22). Ex vivo T-cell stimulation and expansion
before autologous administration has also been reported to cause
massive cytokine release, which necessitates intensivemonitoring
of patients (23). Little is known about how combined treatment
with immune checkpoint inhibitors affects immunosuppression
within the solid tumor microenvironment or whether it
modulates adoptive T-cell function and behavior in vivo. Flow
cytometry and other in vitro assays are limited, as they do not
provide information on the spatial and temporal heterogeneity
of T-cell response within living organisms, a hallmark of most
tumors and a major driver of therapeutic failure. In vivomethods
to dynamically study T-cell distribution, motility, and interaction
with resident cellular subpopulations have the potential to reveal
novel mechanisms of action as well as efficiently informing
on the efficacy of treatments used in combination with these
cell therapies. In particular, in vivo imaging can reveal spatial
and temporal heterogeneity at high resolution which is difficult
with other approaches. There is currently an unmet need for
novel imaging approaches to study adoptive T-cell motility
within the solid tumor microenvironment, as well as how
immune modulation with checkpoint inhibitors can affect T-cell
infiltration and migration patterns.
Intravital imaging using multiphoton microscopy is an
example of an imaging tool that can be used for the direct
visualization and characterization of cell behavior and
spatiotemporal dynamics of physiological processes within
living organisms. The technique has been used for studying
various aspects of innate and adaptive immune responses to
cancer, infection and inflammatory disorders at single-cell
resolution (24, 25), and is complementary to macroscopic
imaging techniques for in vivo cell tracking, such as positron
emission tomography (PET), single-photon emission computed
tomography (SPECT) and magnetic resonance imaging
(MRI) (26–28).
In this study, intravital imaging was used to evaluate
adoptive T-cell morphology, mobility and trafficking in the
solid tumor microenvironment of immunocompetent mice. A
syngeneic model of ovalbumin-expressing mouse melanoma
with adoptively transferred green-fluorescent OT-1+ cytotoxic
T-cells was used to study antigen-specific T-cell behavior in skin-
flap tumors. This experimental setup used a widely available
transgenic model to demonstrate the feasibility of studying T-
cell mobility and behavior in situ. Treatment with immune
checkpoint inhibitors was used as a model system to demonstrate
the potential applications of this methodology and the work has
revealed novel morpho-dynamic characteristics of ATC behavior
following therapy with ICIs. This approach could be used to
investigate and screen novel combinational ATC-drug regimens
in the future, which in turn could have important implications
for designing clinical trials incorporating cell therapy and
immune modulation.
MATERIALS AND METHODS
Cell Culture
The mouse metastatic melanoma cell line B78ChOva-mCherry
was obtained from Prof. Matthew F. Krummel (University of
California, San Francisco). This transgenic line expresses the
specific antigen chicken ovalbumin (OVA) peptide tagged to
a mCherry reporter that can be recognized by antigen-specific
OT-I+ T-cells (29). The line was generated via the transfection
of B16 parental cells with a vector containing mCherry and
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chicken ovalbumin genes intercalated with two self-cleavable
porcine teschovirus-1 2A (P2A) sequences. Cells tested negative
for mycoplasma and rodent infectious agents and were cultured
in RPMI-1640 media containing L-glutamine (Gibco R©, Thermo
Fisher Scientific, UK) with 10% heat-inactivated fetal bovine
serum (LabTech, UK) and 100 U/mL penicillin-streptomycin
(Invitrogen, USA) in a humidified atmosphere of 5% CO2
at 37◦C.
Mouse Models
All animal procedures were approved by the Animal Welfare
and Ethics Review Committees of the University of Cambridge
and the Babraham Institute in Cambridge and were carried
out in accordance with the United Kingdom Home Office’s
Guidance on the Operation of Animals (Scientific Procedures)
Act 1986.
OT-I x GFP mice were generated by crossing OT-1 mice (30)
with UBI-GFP mice (31) in the C57BL/6 background and the
offspring were genotyped using the following PCR primers:
OT-I T-cell Receptor (TCR) Vα2 chain
Forward 5′-CAGCAGCAGGTGAGACAAAGT-3′ and
Reverse 5′-GGCTTTATAATTAGCTTGGTCC-3′
GFP
Forward 5′-AAGTTCATCTGCACCACCG-3′ and
Reverse 5′-TCCTTGAAGAAGATGGTGCG-3′.
Female mice (12–14 weeks old) that were positive for both
OT-I and GFP were used as T-cell donors into recipient female
C57BL/6 mice (8–10 weeks old).
Generation of a Syngeneic Mouse
Melanoma Model for Immunotherapy and
T-Cell Intravital Imaging
Syngeneic mouse melanoma models for immunotherapy
were established by subcutaneous injection of B78ChOva-
mCherry cells (1.5 × 105 cells in 100 µl PBS) in the left
flank of C57BL/6 mice on Day 0. Tumors were palpable
by Day 10.
Naïve OT-I+ CD8+ GFP+ T-cells were isolated and purified
from donor OT-I x GFP transgenic mice (non-tumor bearing
females) for adoptive transfer into recipient female tumor-
bearing mice with 10-day old tumors. This was conducted based
on the following procedures:
The peripheral and mesenteric lymph nodes were first
harvested from donor OT-I x GFP mice into MACS buffer
(PBS containing 0.5% bovine serum albumin and 2mM EDTA).
Lymph nodes pooled from a single donor OT-I x GFP
mouse produced sufficient T-cells for adoptive transfer into 10
mice. In each trial, we pooled CD8+ T-cells from the lymph
nodes of 2 donor mice for injection into 18 recipient tumor-
bearing mice, which were then randomly assigned into different
treatment cohorts.
1. The lymph nodes were extruded through a 40µm cell strainer
(FalconTM, Thermo Fisher Scientific, UK) into a petri dish,
rinsed with MACS buffer and centrifuged at 1,500 rpm for
5min. The cells were then resuspended at 108 cells/ml in
MACS buffer.
TABLE 1 | List of FITC-conjugated antibodies for isolation and purification of
CD8+ T-cells from lymph nodes of donor OT-I x GFP mice using the negative
selection magnetic sorting method.
Antibodies Clone Removal of non-target cells
CD4 H129.19 CD4 T-cells
CD19 MB19-1 B-cells
CD49b DX5 NK cells
MHCII i[Ab] AF6-120.1 Antigen-presenting cells
CD25 PC61 Activated T-cells
CD69 H1.2F3 Activated T-cells
2. CD8+ T-cells were enriched by the negative selection
magnetic sorting method with fluorescein isothiocyanate
(FITC)-conjugated antibodies (Biolegend, USA) at 2.5µg/ml
as shown in Table 1.
3. The cell suspension was incubated with FITC-conjugated
antibodies in 1ml MACS buffer at 4◦C for 30min.
4. Incubation of the cell suspension was terminated by adding
10mlMACS buffer to the antibody labeled cells. The cells were
then pelleted by centrifugation at 1,200 rpm for 7min.
5. 107 cells labeled with antibodies were incubated with anti-
FITC microbeads (Miltenyi Biotec, Germany) at 1:10 dilution
on a rotator at 4◦C for 20min.
6. Incubation of cells was terminated by adding 10ml MACS
buffer to the antibody labeled cells. The cells were then pelleted
by centrifugation at 1,500 rpm for 5min and resuspended in
1ml MACS buffer.
7. Elution of the cell suspension was carried out through a LS
column set up on a MidiMACSTM Separator (Miltenyi Biotec,
Germany). The eluent (isolated CD8+ T-cells) were collected
and the number of cells were counted.
8. Purity of the OT-I+ CD8+ GFP+ T-cells were verified by
flow cytometry (BD LSRFortessaTM analyzer, BD Biosciences,
USA) with CD4-PE (clone GK1.5), CD8a-APC (clone 53–
6.7) and TCRVα2-PerCPCy5.5 (OT-I; clone B20.1) antibodies
(Biolegend, USA), as well as the expression of GFP.
9. 105 T-cells were adoptively transferred into each syngeneic
tumor mouse by intravenous injection.
Treatment With Immune Checkpoint
Inhibitors
To evaluate the experimental approach for intravital imaging of
adoptive T-cells in the context of cancer immunotherapy using
immune checkpoint inhibitors, treatment was administered
intravenously into mice with established tumors from Day 13
after the adoptive T-cell transfer experiment every 2–3 days over
the course of 1 week into three treatment cohorts with n = 18
mice per group from three independent experiments: (1) vehicle
control; (2) anti-PD-L1 monotherapy; and (3) anti-CTLA-4 +
anti-PD-L1 (10 mg/mL each; anti-CTLA-4: clone 9H10; anti-PD-
L1: clone 10F.9G2; InVivoMAbTM, Bio X Cell, USA).
Tumor growth was monitored from Day 11 onwards by
caliper measurements every 2–3 days, and volumes were
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calculated using an ellipsoid formula for best estimation of the
tumor mass: volume (mm3) = (pi /6) x a x b x c, where a, b, and c
represent the three orthogonal axes of the tumor. Only mice with
palpable tumors from Day 10 were included for adoptive transfer
experiment, intravital imaging and subsequent analysis.
Surgical Preparation of Skin-Flap Tumors
for Intravital Imaging
Surgical preparation of the skin-flap tumors for intravital
imaging was conducted based on the following procedures:
1. Anesthetization of the mouse was carried out in an induction
chamber using 4% isoflurane with 21% oxygen and balance
nitrogen as the carrier gas at a flow rate of 1.0 L/min. The time
duration for anesthetization of the mouse was about 3–5min.
2. Once the mouse was breathing deeply and slowly, it
was transferred to a surgical stage equipped with a
stereomicroscope. Surgical anesthesia was performed with a
1:1 mixture of Hypnorm (25 mg/kg) and Hypnovel (12.5
mg/kg) (VetaPharma Ltd, UK) delivered via intraperitoneal
injection. To ensure that the mouse was properly anesthetized
for the surgical procedure, a footpad pinch was performed to
ensure no pedal withdrawal reflex.
3. The limbs of the mouse were then secured to the surgical
platform using surgical tapes.
4. Hair was removed from the ventral surface around the
imaging site using a shaver and the area was disinfected with
70% isopropanol wipes and betadine.
5. The surgical procedure began by first making a single ventral
midline incision about 3mm above the urethra to the xiphoid
process using the first pair of sterile scissors and teethed
forceps. Care was taken not to puncture or cut through
the peritoneum.
6. Using a second pair of sterile scissors and serrated forceps, the
skin was gently detached away from the peritoneal cavity, with
the subcutaneous tumor and draining lymph node attached.
Care was taken to ensure no damage to themajor blood vessels
to maintain blood perfusion.
7. The external surface of the skin-flap tumor was then
secured to a deep-well heated perfusion chamber (Series 40
Perfusion Chamber, Warner Instruments, Harvard Bioscience
Inc., USA) using veterinary-grade tissue adhesive glue (3M
Vetbond, USA) such that the bulk of the tumor was on top and
was seated flat once the mouse was placed on the microscope
stage and was not hindered by the mouse body and mobility
of its hind limbs. To minimize tissue dehydration, the exposed
skin-flap tumor was submerged with surgical saline solution.
The surrounding parts of the exposed tissue was covered with
sterile gauze to protect against contamination.
8. Following surgery, the mouse was transferred immediately
onto a portable microscope stage insert equipped with a
heating pad (Harvard Apparatus, USA) to maintain its
temperature at 37
◦
C to prevent hypothermia. The mouse was
gently secured to the stage insert using surgical tapes.
9. Both the mouse on the stage insert and the perfusion chamber
were transferred onto a microscope stage covered with sterile
gauze. Care was taken to ensure that the tumor was correctly
positioned on top and in the center of the imaging port of
the microscope stage. The perfusion chamber was secured
to the microscope stage with lab tapes to minimize motion
artifacts during imaging. This was followed by the attachment
of the inlet and outlet ports of the perfusion chamber to a
vacuum pump system (VACUSAFE, Integra Biosciences, UK)
for constant bathing of the exposed skin-flap tumor with
warm oxygenated saline during imaging.
10. For continuous anesthesia and rehydration of the mouse
during imaging, an intraperitoneal line was inserted with a
winged infusion set attached to a 1ml syringe containing 100
µl saline. The animal was injected with 50 µl of saline and 1:1
Hypnorm/Hypnovel mix at 1 h intervals until the end of the
imaging session.
11. Vital signs monitoring during imaging was conducted using a
SpO2 pulse oximeter and temperature rectal probe (Harvard
Apparatus, USA).
Intravital Imaging of Antigen-Specific
T-Cells
Live imaging of OT-I+ CD8+ GFP+ T-cells within tumors
was conducted on Day 21 on mice from all treatment cohorts
(n = 6 mice per group from three independent experiments).
Mice were immediately imaged after surgical preparation of
skin-flap tumors on a Zeiss LSM 7 MP system equipped
with W Plan-APOCHROMAT 20X/1.0 NA objective and Zeiss
ZEN image acquisition software (Carl Zeiss Ltd, Germany).
Fluorescence excitation and emission was achieved using a
tunable titanium:sapphire two-photon source (Chameleon Ultra
II, Coherent Laser Group, USA).
1. The appropriate laser wavelength (720–930 nm) and laser
power (18%) were first set.
2. Epifluorescence illumination (pE-300white LEF illumination
unit, CoolLED Ltd, UK) was used to locate the tumor via the
microscope eyepiece and a random tissue region where GFP+
T-cells and mCherry+ tumor cells were clearly visualized and
selected for imaging.
3. The live imaging and second harmonic generation (SHG)
modes were turned on and the focus was adjusted to locate
collagen fibers in the tumor periphery. Adjustment to the
upper and lower limits of the image stack were made: the
upper limit or first imaging slice was set at a point where the
SHG signal was just about to disappear, whilst the lower limit
of the z-series was set bymoving the objective to themaximum
imaging depth (100–120µm).
4. 3D time-lapsed images were acquired with an in-plane (xy)
pixel resolution of 512 × 512µm at increments of 5–6µm in
the z plane and a frame interval of 30 s. Recording time was
∼30min per scan.
5. The emitted light and SHG signals from the T-cells, tumor
cells and collagen fibers were, respectively, collected with the
bandpass filters for green (BP 520/60), red (BP 607/70) and
second harmonic generation (SHG) (BP 447/60) and non-
descanned PMT detectors.
6. Imaging was repeated at two other random regions of the
tumor up to a total maximum period of 2 h in each mouse.
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7. At the end of the intravital imaging experiment, the
mouse was euthanized in a CO2 chamber. Once the
breathing ceased, cervical dislocation was performed to ensure
complete euthanasia.
Flow Cytometry
Whole tumors with intact stroma were harvested from the mice
after intravital imaging for subsequent functional analysis on flow
cytometry. Single-cell suspension were prepared from tumors of
no more than 1 g using gentleMACS Tumor Dissociation Kit
(Miltenyi Biotec, Germany) and 40µm cell strainers (FalconTM,
Thermo Fisher Scientific, USA). 5 × 106 cells were incubated
with Fc-block (eBioscience, USA) and stained in 2% FACS buffer
at 4
◦
C for 30min with fluorochrome-conjugated antibodies
(Biolegend, USA) against immune markers including CD45-
BUV395 (clone 30-F11), CD8a-APC (clone 53-6.7), CD44-
PerCPCy5.5 (clone IM7) and PD-L1-PE (clone 10F.9G2),
as well as fixable viability dye eFluor 780 (Thermo Fisher
Scientific, USA) for dead cells discrimination. Flow cytometry
was conducted on BD LSRFortessaTM analyzer (BD Biosciences,
USA), with appropriate lasers and filters, unstained and
compensation controls. Data were analyzed using FlowJoTM
(Tree Star Inc., BD Biosciences, USA).
Immunofluorescence
Tumors from 18 mice per treatment cohort were fixed in
4% paraformaldehdye, embedded in low-melting agarose
(Sigma Aldrich, USA) and sectioned into 300µm thick slices
on a VT1000S vibratome (Leica Microsystems, Germany).
Immunofluorescence staining of the tumor stroma was
performed at 4
◦
C overnight in 0.1% sodium azide and 5% bovine
serum albumin in PBS using rabbit anti-mouse Fibronectin
(clone ab2413, Abcam, UK) and goat anti-rabbit Alexa Fluor
405 secondary antibodies (Molecular Probes, Life Technologies,
USA); whilst tumor blood and lymphatic vessels were stained
using rabbit anti-CD31 conjugated to Alexa Fluor 647 (clone
MEC13.3, Biolegend). Stained sections were washed three times,
mounted on custom-made deep well-microscope slides, and
imaged in 10 random field-of-views on Zeiss 780 confocal
microscope (Carl Zeiss Ltd, Germany).
Image Processing and Analysis
Images were processed and analyzed using Icy, an open-source
platform for bioimage analysis (32) and integrated with ImageJ
version 1.52e (National Institute of Health, USA). All images
were maximum intensity projected and attenuation corrected
using the Debleach plugin, followed by Gaussian denoising
and intensity thresholding for the detection of individual
GFP+ T-cells.
Analysis of Immunofluorescence Images
The Edge Detection and Spot Detector plugins from the Icy
software package were used for the semi-automated detection of
the number of T-cells on immunofluorescent images. Histogram
analysis was performed on the binary mask of the grayscale
images to evaluate the spatial distribution of T-cells within the
tumor microenvironment based on the individual T-cell GFP
signal location in the xy coordinates horizontally from the tumor
periphery toward the tumor core using Matlab (Mathworks,
USA). First order statistical measure of image heterogeneity was
computed based on the histogram kurtosis. Kurtosis is a measure
of the peakedness in the distribution of gray values around the
mean value (heavy-tailed or light-tailed relative to a normal
distribution) i.e., heterogeneity of T-cell GFP signal distribution
from tumor periphery to tumor core. Higher (positive) kurtosis
reflects T-cells that are distributed more toward the tumor core
in the immunofluorescent images.
Analysis of Time-Lapsed Videos
Time-lapsed videos from intravital imaging were corrected for
motion artifacts or drifts using the Rigid registration plugin
of the Icy software package. Tracking of individual T-cells was
performed semi-automatically using the Spot Detector plugin
for T-cell centroid identification and Manual Tracking plugin
to determine the mean velocity, displacement and meandering
index. T-cells that could not be tracked for more than 5
timepoints were excluded from the analysis. T-cell velocity was
calculated from the straight-line distance between the point of
origin and the point of termination of a cell track, divided by
the duration of the cell track in minutes. The meandering index
defines track straightness and is the ratio between the T-cell
displacement from its origin and the total path length traveled,
where 1 represents a completely linear cell track or directional
movement (33). Track plots were calculated to demonstrate
the actual migration of T-cells relative to their point of origin.
The Edge Detection and Active Contour Icy software package
plugins were used for semi-automated region of interest (ROI)
segmentation of cell boundary to evaluate the dynamic changes
in T-cell morphology over the imaging timepoints based on the
measurement of cell elongation (34).
Statistical Analysis
Statistical analysis was performed with Prism 5.01 (GraphPad
Software Inc., USA). Data are presented as mean ± standard
error of the mean (SEM) unless otherwise stated. Normality
was assessed using the D’Agostino-Pearson normality test.
Differences between two independent groups were evaluated
using unpaired t-test for measurements that are normally
distributed, Mann–Whitney test for data that are non-
Gaussian. For comparison of three or more independent
groups, the Kruskal–Wallis test followed by Dunn’s multiple
comparison post hoc test was used. A p < 0.05 was considered
statistically significant.
RESULTS
Development of a Syngeneic Mouse
Melanoma Model for Immunotherapy and
T-Cell Intravital Imaging
A schematic diagram for the generation of a syngeneic mouse
melanoma model used in these T-cell intravital imaging
experiments is shown in Figure 1A. B78ChOva-mCherry is an
amelanotic clone derived from the immunologically cold mouse
B16 melanoma cell line. It is an ideal syngeneic melanoma model
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for intravital imaging and immunotherapy for the following
reasons: the presence of the BRAFV600E mutation in B78
murine melanoma is reflective of ∼50% of human malignant
melanomas which have activating BRAF mutations; up to 20%
of human melanoma are amelanotic or partially pigmented, and
have poorer prognosis than pigmented tumors (35). The lack of
melanin production in B78 due to a mutation in the tyrosinase-
related protein 1 gene, minimizes autofluorescence in the green
and red channel during optical imaging and enables better
visualization of the dynamics of live GFP+ T-cell movement at
the tumor site. Some studies have suggested that B78 is a weakly
immunogenic tumor similar to its melanotic counterpart B16
melanoma, and immunotherapy such as vaccination strategies
have been shown to enhance immune response in B78 (36,
37). B78ChOva-mCherry expresses the foreign antigen chicken
ovalbumin that enabled T-cell targeting of the tumor and an
mCherry reporter for visualization of the tumors. SHG imaging
of fibrillar collagen and myofibers allowed location of the tumor
periphery during imaging (Figure 1B). Cross-breeding of OT-I
mice and GFP mice generates CD8+ T-cells with cell membrane
expression of the T-cell receptor comprising the alpha (Vα2)
and beta (Vβ5) chains of OT-I that can specifically recognize
ovalbumin (30, 38). Strong ubiquitous expression of the GFP
reporter in the cytoplasm enabled measurements of T-cell
motility, dynamic changes in cell morphology and distribution
within the solid tumor microenvironment (31), without the need
for additional antibody labeling during live imaging.
T-cells purified from the lymph nodes of OT-I x GFP mice
were typically more than 90% positive for both OT-I and GFP
(Figure 1C). As the infusion dose of antigen-specific T-cells can
have an impact on the magnitude of tumor regression, as well as
the number of viable tumor cells and T-cells that could still be
detected on Day 21 during intravital imaging, initial experiments
were performed to adoptively transfer titrated doses of OT-I+
CD8+ GFP+ T-cells into mice bearing established B78ChOva-
mCherry tumors on Day 10. Infusion with increasing numbers
of T-cells caused a greater delay in tumor growth compared to
lower numbers of injected cells (Figure 1D). Infusion with 105
T-cells was selected for subsequent drug treatment and imaging
experiments as tumor growth was slower than at lower T-cell
doses but not as severely delayed at Day 21 compared to infusion
with 106 T-cells.
Immune Checkpoint Inhibition Enhanced
T-Cell Recruitment and Activation
To demonstrate the effects of immune checkpoint inhibitors
on adoptive T-cell response in this experimental model for
intravital imaging, we first administered 105 OT-I+ CD8+ GFP+
T-cells on Day 10 and allowed the transgenic T-cells to be
reconstituted into the wild-type mouse immune system for
at least 48 h before treatment from Day 13 with monoclonal
antibodies targeting PD-L1 and/or CTLA-4 every 2–3 days over
the course of 1 week. Rapid exponential tumor growth from
Day 10 was observed in mice given adoptive T-cell transfer
alone (mean tumor volume 288 mm3). By Day 21, combined
therapy with immune checkpoint inhibitors (ICI) resulted in
slower tumor growth rates. Combined adoptive T-cell transfer
with anti-CTLA-4 and anti-PD-L1 therapy (132 mm3) was only
marginally more effective than anti-PD-L1 monotherapy (144
mm3) (Figure 2A). The mass of tumors harvested at the end
of the imaging experiment on Day 21 was more variable in all
treatment cohorts, but also suggested combination therapy was
more effective than monotherapy (Figure 2B).
Flow cytometric analysis of the harvested tumors on Day
21 after intravital imaging showed a greater percentage of
endogenous and adoptive CD8+ T-cells infiltration within ICI-
treated tumors (p < 0.01 for vehicle control vs. combined anti-
CTLA-4 and anti-PD-L1). Expression of the T-cell migration,
activation and effector/memory response marker CD44 was
higher in tumors treated with combined anti-CTLA-4 and anti-
PD-L1 therapy (p< 0.05), compared to control mice (Figure 2C).
Further analysis revealed an overall reduction in PD-L1+ cell
populations in ICI-treated tumors, which can be accounted for
by immune-mediated cell death (p < 0.05 for vehicle control
vs. anti-PD-L1 monotherapy; p < 0.01 for vehicle control vs.
combined anti-CTLA-4 and anti-PD-L1; Figure 2D).
Greater T-Cell Infiltration and
Heterogenous Distribution in Experimental
Model
To evaluate how immune checkpoint inhibitors targeting CTLA-
4 and PD-L1 improve adoptive T-cell migration into tumors
in this experimental model, image-based analysis of the spatial
distribution of the OT-I+ CD8+ GFP+ T-cells in the harvested
tumors was performed (n = 18 mice from each treatment
cohort). A greater number of GFP+ T-cells were detected in
both peritumoral and intratumoral regions of tumors treated
with ICI, compared to tumors treated with T-cell transfer alone
(p < 0.001; Figures 3A,B). Histogram analysis showed a more
heterogeneous spatial distribution of adoptive T-cells within ICI-
treated tumors (kurtosis = 2.07 for PD-L1 monotherapy; 2.11
for combined anti-CTLA-4 and anti-PD-L1 therapy) compared
to tumors treated with T-cell transfer alone (kurtosis = 1.90).
More T-cells were detected at the invasive margins and toward
the tumor core in tumors treated with combined anti-CTLA-4
and anti-PD-L1 therapy (Figure 3C). The pan-endothelial cell
marker CD31 is expressed on blood and lymphatic vessels (39):
higher CD31+ vessel counts were detected in ICI-treated tumors
than in the control mice. Spearman’s correlation analysis showed
a positive relationship betweenGFP+ T-cell numbers and CD31+
vascular density (Figure 3D).
Distinct Adoptive T-Cell Behavior and
Cellular Morpho-Dynamic Changes
Intravital imaging using the methodology described in
B78ChOva-mCherry was performed to study the in vivo
behavior and cellular morpho-dynamics of adoptive T-cells.
Immune checkpoint blockade was used as an example to
demonstrate this approach. Individual GFP+ T-cells could be
resolved and tracked up to the penetration depth limit of 100µm
beneath the tumor periphery of a skin-flap tumor model.
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FIGURE 1 | Generation of a syngeneic mouse melanoma for immunotherapy and T-cell intravital imaging. (A) OT-I+ CD8+ GFP+ T-cells were isolated from the lymph
nodes of OT-I x GFP mice and adoptively transferred into C57BL/6 immunocompetent mice 10 days after subcutaneous implantation of B78ChOva-mCherry mouse
melanoma tumors. Mice were treated with immune checkpoint inhibitors or vehicle control over 1 week and intravital imaging was conducted on Day 21. (B) The
implanted tumors were amelanotic and expressed ovalbumin and mCherry for OT-I T-cell targeting and localization of the tumor-stroma interface by second harmonic
generation imaging of collagen fibers. (C) Purified CD8+ T-cells for the adoptive T-cell transfer experiments were positive for both OT-I and GFP based on PCR
genotyping and flow cytometry. (D) Mean tumor growth rates over 21 days of mice infused with titrated doses of OT-I+ CD8+ GFP+ T-cells on Day 10 (n = 6 mice for
each titration group). Tumor volume changes at each timepoint following administration of 105 T-cells are shown as mean ± SEM. The scale bar in (B) represents
50µm. Graphics in (A) were original art illustrated by the author (DL).
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FIGURE 2 | Synergistic effects of immune checkpoint inhibitors on T-cell recruitment and activation in the experimental model for intravital imaging. (A) Tumor growth
rates of mice treated with adoptive T-cell transfer alone (vehicle control) or in combination with monoclonal antibodies targeting PD-L1 or CTLA-4. (B) Tumor mass
harvested at the end of the intravital imaging experiment on Day 21. (C) Flow cytometric analysis of harvested tumors showed enhanced recruitment and activation of
adoptive and endogenous T-cells based on the expression of the CD8 marker for cytotoxic T-cells and the CD44 marker for T-cell migration, activation and
effector/memory response. (D) Effects of immune checkpoint inhibitors on PD-L1+ immune and non-immune components of the tumors across treatment cohorts.
Unpaired t-test was performed to test for differences in tumor volumes and tumor masses on Day 21 between ICI-treated cohorts and the vehicle control (A,B).
Kruskal–Wallis test with post-hoc Dunn’s multiple comparison analysis was performed to test for differences between all three independent treatment cohorts (C,D);
*P < 0.05; **P < 0.01.
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FIGURE 3 | Demonstration of the enhanced infiltration and heterogeneous distribution of adoptive T-cells in tumors treated with immune checkpoint inhibitors.
Immunofluorescence analysis was performed on harvested tumors obtained on Day 21 of the experiment and 11 days after adoptive T-cell transfer and 8 days after
immune checkpoint inhibition was initiated (n = 18 mice per treatment cohort). (A) Spatial distribution of OT-I+ CD8+ GFP+ T-cells in tumors across treatment
cohorts. (B) Image channel with GFP+ signal was extracted from maximum-intensity projected immunofluorescence images (300µm slice thickness; 10 fields-of-view
taken horizontally from stroma, invasive margin and toward tumor core). Edge Detection and Spot Detector plugins were used for automated detection of GFP+
(Continued)
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FIGURE 3 | T-cells. Binary masks of the T-cell xy coordinates were used to calculate total GFP+ T-cells counts in peritumoral and intratumoral regions of the tumors
and (C) the histogram analysis on the spatial distribution of adoptive T-cell within the solid tumors. (D) CD31+ vessel counts (mean ± SEM) and Spearman’s
correlation analysis of CD31+ vessel counts and GFP+ T-cell counts. Mann–Whitney test was performed for testing differences in total GFP+ T-cell counts between
the vehicle control and ICI-treated cohorts (B). Kruskal–Wallis test with post hoc Dunn’s multiple comparison analysis was performed to test for differences between
three independent treatment cohorts (C,D); **P < 0.01; ***P < 0.001. Scale bars in (A) represent 100µm.
The majority of T-cells at the tumor periphery were observed
moving slowly along the collagen fibers with Lévy-like trajectories
consisting of clusters of small steps interspersed with long
walks (40). T-cells migrating in the collagen-dense areas of the
tumor periphery demonstrated significantly faster movements
(4.27 ± 0.11 µm/min) than T-cells within the tumor core (1.36
± 0.04 µm/min; p < 0.001; Figure 4A). These peritumoral
T-cells displayed more elongated lamellipodia at the leading
edge and shortened uropods at the rear end with more rapidly
changing morphology (elongation index of 1.60 ± 0.01) and less
meandering or confined movements (meandering index of 0.37
± 0.01) than T-cells in the tumor core (elongation index of 1.31
± 0.01; meandering index of 0.49± 0.01; p< 0.001). In contrast,
intratumoral T-cells exhibited a more compact morphology with
dynamic formation and contraction of filopodia as they navigated
the tumor core. Some T-cells in close contact with the tumor cells
were stationary, rounded and appeared to undertake probing
behavior in the local environment, consistent with cell-cell
interactions (Figures 4B,C).
Adoptive T-cells exhibited diverse migration patterns in the
tumors of mice across all treatment cohorts. More T-cells
were detected in the tumor periphery and tumor core of mice
treated with ICIs, and were observed traveling at significantly
lower mean velocities (1.75 ± 0.07 µm/min for anti-PD-L1
monotherapy; 2.15 ± 0.08 µm/min for combined anti-CTLA-4
and anti-PD-L1 therapy) than T-cells from the vehicle control
cohort (4.60 ± 0.25 µm/min; p < 0.001; Figures 5A–D). T-cells
in ICI-treated tumors exhibited a much shorter displacement
from their original position (14.38 ± 0.99µm for anti-PD-
L1 monotherapy; 21.32 ± 1.38µm for combined anti-CTLA-
4 and anti-PD-L1 therapy; p < 0.001) and more confined
movements (meandering index of 0.42 ± 0.01 for anti-PD-L1
monotherapy and 0.47 ± 0.01 for combined anti-CTLA-4 and
anti-PD-L1 therapy; p < 0.05) than T-cells within tumors of
mice from the vehicle control group (mean displacement of
50.78 ± 6.35µm; meandering index of 0.41 ± 0.03; Figure 5D;
Supplementary Videos 1–3). T-cell velocities were higher in the
peritumoral region compared to intratumoral region in mice
from all treatment cohorts.
Qualitative analysis of the migration behavior patterns of
T-cell populations in the tumors of mice given different
treatments were performed by plotting the mean velocities vs.
the meandering index of individual T-cell migration tracks
(Figure 5E) (41–43). For further comparison on the differences
in T-cell behavior across treatment cohorts, each migration plot
was subdivided into quadrants based on the mean velocity
(2.16 µm/min) and meandering index (0.45) of all adoptive T-
cells measured in tumors of mice from all treatment cohorts.
Each numbered quadrant on the migration plots represents
different T-cell migration patterns within the solid tumor
microenvironment: (1) actively migrating T-cells returning to
their origin i.e., highmean velocities and lowmeandering indices;
(2) T-cells with directional and sustained movements i.e., fast
movements with minimal stop periods as reflected by the high
mean velocities and highmeandering indices; (3) T-cells with low
motility i.e., lowmean velocities and lowmeandering indices; and
(4) T-cells with non-sustained motility i.e., low mean velocities
and but high meandering indices which implied that these T-cells
have more prolonged periods of immobility and only actively
migrate during certain periods of the observation. Adoptive T-
cells in ICI-treated mice exhibited variable migration patterns,
with cells distributed in all four quadrants of the T-cell behavior
distribution. An enriched number of intratumoral T-cells were
observed in quadrants 3 and 4, implying the presence of more
T-cells with non-sustained and low mobility with short periods
of active movements, consistent with the behavior of activated
T-cells engaging tumor targets. A higher number of fast-moving
T-cells (both with directional/sustained migration and with a low
meandering index i.e., quadrants 1 and 2 above) were observed
in tumors of mice treated with combined anti-CTLA-4 and
anti-PD-L1 therapy compared to anti-PD-L1 monotherapy. The
majority of these fast-moving T-cells in ICI-treated mice were in
the peritumoral region.
DISCUSSION
Efficient T-cell infiltration, homing, and activation within solid
tumors is crucial for the success of cancer immunotherapy.
Increasing evidence suggests that T-cell migration into peripheral
tissues is not random, but governed by a combination of cell-
intrinsic locomotion events (driven by actin polymerization
and myosin-induced contractions), physical guidance from the
microenvironment including the stroma, chemical cues (such
as cytokines, chemokine gradients), the density of cognate
antigens and antigen-presenting cells (APCs), as well as the
presence of co-stimulatory molecules and immune checkpoints
(44, 45). In solid cancers, T-cells are frequently found at
greatest density in peritumoral regions and poorly penetrate
the dense tumor (12, 45). The high density of regulatory T-
cells (Tregs) and myeloid-derived suppressor cells (MDSCs)
that are recruited during tumorigenesis, as well as the presence
of intrinsic cancer-associated fibroblasts, have been shown to
reduce the T-cell response through the expression of PD-L1
and other immunosuppressive molecules (6, 8). Live imaging
of T-cell behavior in the context of tumor immunosuppression
and following pharmacological intervention with immuno-
modulatory drugs could have important implications for
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FIGURE 4 | T-cell migration speeds, trajectories and cellular morpho-dynamic changes during tumor infiltration. (A) Intravital imaging was performed using
multiphoton microscopy with second harmonic generation to detect the stroma-tumor interface and OT-I+ CD8+ GFP+ T-cells infiltrating tumors at a tissue
penetration depth of 100µm. Track plots, velocities, and meandering indices of T-cells were measured from T-cells located separately within the peritumoral and
intratumoral regions. (B) Adoptive T-cells demonstrated different migration patterns from peritumoral to intratumoral regions of the tumors. (C) Analysis of T-cell
morphology changes over the 30min imaging time-course. Mann–Whitney test (A,C) for differences between the means of two independent groups; ***P < 0.001.
Scale bars in (B) represent 10µm.
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FIGURE 5 | In vivo behavior of adoptive T-cells in response to immune checkpoint blockade. (A) Representative images from Supplementary Videos 1–3 and track
plots of OT-I+ CD8+ GFP+ T-cells from both peritumoral and intratumoral regions of tumors across treatment cohorts. (B) Velocity, (C) displacement, and (D)
meandering index of all T-cells from the different treatment cohorts (n = 6 mice per cohort). (E) Individual T-cell tracks were plotted according to their meandering
indices and mean velocities for qualitative analysis of the different migration behavior patterns of T-cell populations in tumors of mice given different treatments, and
quadrants on the plots depicts four populations of T-cells (42–44): (1) actively migrating with return to their origins; (2) directional and sustained movements; (3) low
motility; and (4) T-cells with non-sustained motility (see Results for further explanation of these terms). The Kruskal–Wallis test with post hoc Dunn’s multiple
comparison analysis (B–D) for differences between three independent treatment cohorts was used for statistical analysis; *P < 0.05; ***P < 0.001. Scale bars in (A)
represent 100µm.
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understanding the interaction of T-cells with the tumor and
its environment, as well as studying the functional effect of
novel therapies such as ATC in conjunction with immuno-
modulatory drugs.
Intravital imaging has proven to be an important tool for
understanding the effects of cancer immunotherapy on tumor
eradication (24). The in vivo dynamics of single T-cell behavior,
function, and its complex interactions with the solid tumor
microenvironment can be studied at high spatial resolution
that is not easily achievable by in vitro assays and other
macroscopic imaging techniques such as MRI and PET (26, 27).
Several experimental approaches to intravital imaging can be
utilized for studying T-cell behavior following immunotherapy
in living animals (24, 25): abdominal and dorsal skin-fold
window chambers are available for longitudinal tracking of T-
cell dynamics (46, 47); small tumors can be implanted into the
ear pinnae or footpad for non-invasive imaging (48); skin-flap
tumors can be surgically exposed to gain immediate insights on
T-cell dynamics following treatment. Each of these methods has
advantages and limitations and the choice of method depends
not only on the biological question being addressed, but also
on the extent of technical expertise and equipment required
to carried out the procedure. The use of a skin-flap tumor
model for intravital imaging is limited by the need for surgical
exposure of the tumors for fluorescent imaging. However, unlike
the dorsal skin-fold window chamber or ear tumor models,
skin-flap tumors are essentially subcutaneous implanted tumors
allowed to grow in all dimensions in a similar manner to the
tumor models used in most immunological studies. As tumors
have limited spaces for growth within window chambers or
between the ear dermis, it may be difficult to control the size
of tumor growth and develop a larger established tumor for
assessing immunotherapy. Clamping of the tissues in a dorsal
skin-fold chamber and growing the tumor within the confined
space of the ear dermis can disrupt the normal surrounding
tissues and limit blood perfusion (49). The window chamber
and ear tumor models are also technically challenging for
most researchers, as complex surgery is required to remove
normal tissues to implant the artificial window and tumor
spheroids. This poses a high risk for tissue inflammation and
animal loss, hence careful monitoring during the post-surgical
recovery phase would be required even before the start of
any treatment. Nevertheless, the main advantage of window
chamber and ear tumor models is the opportunity to undertake
longitudinal imaging.
In this study, a combination of intravital imaging followed
by detailed image and functional analysis was performed
in situ, to reveal insights on the function and behavior of
adoptive T-cells in skin-flap tumors. Treatment with CTLA-4
and PD-L1 monoclonal antibodies was used as an exemplar
to demonstrate this experimental approach. In comparison to
the untreated control group, tumors treated with checkpoint
inhibitors demonstrated more adoptive T-cell infiltration at the
invasive margins at the junction between the collagen fibers
detected with second harmonic generation, and the mCherry-
labeled tumors, as well as the upregulation of CD44, an
adhesion marker which mediates T-cell migration into the tumor
interstitium (41). Treatment with anti-PD-L1 monotherapy
resulted in a substantially lower tumor mass compared to
tumors treated with T-cell transfer alone, as well as increased
depletion of PD-L1+ tumor cells, leukocytes, stromal and
endothelial subpopulations within the tumor microenvironment
at Day 21.
We had used this experimental setup to show that
adoptively transferred T-cells are spatially heterogeneous
within tumors. T-cells were recruited mainly to the stromal
regions within tumors, with some zones completely devoid
of T-cell infiltration. A similar spatial heterogeneity has
been previously observed at a macroscopic level using MRI
cell tracking methods, in which significant intratumoral
heterogeneity in T2 signal has been reported in a B16-OVA
melanoma model adoptively transferred with OVA-specific
CD8+ T-cells labeled with iron oxide nanoparticles (50). In
our study, adoptive T-cells were recruited in greater numbers
toward the tumor core following immune checkpoint inhibition.
This observation at the microscopic level is in concordance
with previous PET studies using anti-CD8 radiolabeled
antibodies in which more intratumoral tracer uptake was
observed in B16.F10 melanoma tumors that responded to
CTLA-4 therapy, whilst the non-responders displayed a
more peripheral distribution in the detected signal (51). In
a separate study, higher intratumoral tracer was observed in
BALB/c mice bearing CT26 colorectal tumors responding
to PD-L1 therapy, whilst the non-responders displayed a
peripheral rim of activity (52). The proximity of CD8+ T-
cells to the tumor cells and the greater distribution toward
the tumor core seems to be an indicator of tumor control
and treatment response. These findings at both microscopic
and macroscopic scales resemble human solid cancers, in
which CD8+ cell infiltration at the invasive margin has been
observed in melanoma patients responding to anti-PD-1
therapy (45).
Both CTLA-4 and PD-1/PD-L1 signaling pathways have
been implicated in many aspects of T-cell function, motility
and migration into peripheral tissues. CTLA-4 is a negative
regulator of T-cell mediated immune response and acts
predominantly during the priming phase of early T-cell
activation following antigen encounter in secondary lymphoid
organs (12). Expression of CTLA-4 on T-cells upon TCR
activation can compete with the co-stimulatory receptor CD28
for binding to B7 ligands and dampens CD28 signaling
which is usually required for activating downstream processes
involved in the regulation of cytoskeletal reorganization and
integrin-mediated T-cell adhesion during tissue infiltration,
such as phosphoinositide-3 kinase (PI3K) and small Rho
GTPase Cdc42 signaling (53, 54). CTLA-4 has also been
shown to interfere with T-cell activation by disrupting the
process of antigen-presentation by APCs in the lymph nodes
and the formation of an immunological synapse through
increased T-cell motility and limited dwell times around
dendritic cells, as proposed by the “reverse-stop signal”
mechanistic model of CTLA-4 inhibitory function (44, 55).
This was further evidenced by reported cases of systemic
lymphoproliferation and enhanced T-cell infiltration into tumors
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and other non-lymphoid organs in CTLA-4 knockout mice
and both human and mice treated with anti-CTLA-4 (12,
44). Similarly, PD-1/PD-L1 signaling has been known to
inhibit T-cell activation and acts predominantly on effector
CD8+ T-cell function. CTLA-4 and/or PD-L1 blockade in
tumors has been demonstrated to act via the depletion of
regulatory and immunosuppressive cell types such as Tregs
and MDSCs and reinvigorating exhausted T-cells to facilitate
tumor entry for more effective tumor eradication (6, 17). The
exact mechanism by which PD-1/PD-L1 signaling inhibits T-
cell entry into tumors has yet to be elucidated and may be
tissue-dependent. PD-1/PD-L1 signaling has been known to
suppress PI3K activities downstream of CXCR5 signaling in
activated CD4+ T-cells and inhibit their recruitment into the
splenic lymphoid follicles for follicular T helper cell development
during T-cell dependent B-cell response (56). In contrast,
therapeutic blockade of PD-1 and PD-L1 has been shown
to restore T-cell motility in the presence of high viral loads
during the early stages of chronic lymphocytic choriomeningitis
viral infections in mice (57). As CTLA-4 and PD-L1 are
implicated in many aspects of T-cell biology, and monoclonal
antibodies targeting these two immune checkpoint proteins are
clinically available (12, 17), these pathways could be potentially
exploited to improve the efficacy of adoptive T-cell therapy in
solid tumors.
Live imaging of adoptive T-cells performed here has revealed
insights on the morpho-dynamics of T-cell within the solid
tumor microenvironment with and without ICI treatment. T-
cells at the tumor periphery traveled at higher velocities in a
mixed Lévy and ballistic-like random search mode along the
collagen fibers, with straighter trajectories and rapidly changing
cell shape and elongation in the direction of travel, compared
to T-cells at the tumor core. This pattern of movement is
consistent with a tumor seeking trajectory: Lévy-like movements
maximize the chances of T-cells encountering their targets
and have been observed in a number of biological scenarios,
ranging from the ecological behaviors of animals foraging for
food to metastatic cancer cells migration at the microscopic
level (40, 58, 59). T-cells located near the invasive margin
and toward the tumor core also exhibited some Lévy-like
locomotion but demonstrated more confined trajectories; these
cells were more compact in shape compared to those in the
periphery, and this morphology and pattern of movement may
reflect cells that have already engaged their targets. Following
treatment with immune checkpoint inhibitors, more T-cells
were detected traveling at lower mean velocities and with
shorter displacement and more meandering tracks compared
to control mice which may also reflect established cell-cell
interactions. T-cells exhibited a range of migration patterns
within the solid tumor microenvironment and mostly displayed
low motility and confined movements within the ICI-treated
tumors at Day 21 (∼11 days after adoptive T-cell transfer
and 8 days after the start of ICI treatment). This low
motility and confined movement suggested that the T-cells
may have identified their antigen target and that cytotoxic
killing may be in progress. Adoptive T-cells were observed
moving more rapidly in the tumors of mice treated with
combined anti-CTLA-4 and anti-PD-L1 therapy, compared to
anti-PD-L1 monotherapy. Here we have identified four distinct
subpopulations of T-cells based on their migration behaviors
with combinations of high vs. low motility, and high vs.
low meandering index. After CTLA-4 and PD-L1 blockade,
there was an enrichment of T-cells with low motility and
high meandering, implying that these T-cells were rapidly
infiltrating into the solid tumor microenvironment to search
for antigen targets. In comparison to PD-L1 monotherapy,
combined CTLA-4 and PD-L1 blockade resulted in only
moderate treatment effects (though not statistically significant)
on tumor shrinkage and T-cell activation and migration i.e.,
a greater number of GFP+ T-cells and populations of cells
with higher velocities were measured in tumors given both
antibodies. CTLA-4 and PD-L1 are known to be expressed on
Tregs and melanoma cells. Treatment with blocking antibodies
can lead to depletion of these two immunosuppressive cell types
within the tumor microenvironment, in addition to the re-
activation of exhausted cytotoxic T-cells (60, 61). The results
from our preliminary analysis in this methods paper suggest
that although the combined effect of CTLA-4 and PD-L1
monoclonal antibodies is synergistic, targeting PD-L1 alone
may be sufficient. Although changes in T-cell proliferation and
survival in the timepoint analyzed may have contributed to
the increase in T-cell infiltration, the effects of CTLA-4 and
PD-L1 antibodies treatment on tumor growth and T-cell function
was still evident i.e., tumors undergoing both monotherapy and
combined therapy were approximately half the volume of the
controls and the number of GFP+ T-cells was 3–5-fold higher in
both the peritumoral and intratumoral regions of the ICI-treated
mice compared to the controls. Further mechanistic studies using
this experimental model will be useful for understanding the
effect of immune checkpoint inhibitors on T-cell behavior in
solid tumors.
In summary, intravital imaging using a skin-flap tumor
model and adoptive transfer of green fluorescent T-cell has
demonstrated the feasibility of this experimental approach
for direct visualization of antigen-specific T-cell function
and behavior within the solid tumor microenvironment, as
well as changes in response to immuno-modulatory drugs.
Evaluation of T-cell motility in this experimental model
following treatment with CTLA-4 and PD-L1 targeted immune
checkpoint inhibitors demonstrated diverse patterns of T-
cell behaviors including change in shape, mean velocities,
and trajectories.
CONCLUSION
In this study, we have demonstrated the feasibility of
using intravital imaging and a transgenic ovalbumin-
expressing mouse melanoma with adoptively transferred
green-fluorescent OT-1+ cytotoxic T-cells to study antigen-
specific T-cell function and behavior. This experimental
approach provides immediate insights on changes in T-
cell migration patterns during tumor infiltration and is
Frontiers in Immunology | www.frontiersin.org 14 July 2020 | Volume 11 | Article 1514
Lau et al. Imaging T-Cells in Cancer
a useful tool for understanding the effects of immuno-
modulatory drugs such as immune checkpoint inhibitors on
T-cell motility.
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Supplementary Video 1 | Intravital imaging of T-cell behavior on Day 21 in a
B78ChOva-mCherry tumor treated with adoptive T-cell transfer alone (vehicle
control). Fast-moving T-cells were detected in the collagen-dense areas of the
tumor periphery, with rapidly elongating cell shape during the time-course of
imaging. T-cells are GFP+ (green), tumor cells are mCherry+ (red), and collagen
fibers were seen as second harmonic signals (cyan).
Supplementary Video 2 | Intravital imaging of T-cell behavior on Day 21 in a
B78ChOva-mCherry tumor treated with PD-L1 monotherapy. An enriched number
of GFP+ T-cells in the tumor periphery and tumor core were identified traveling at
lower mean velocities, shorter displacement and with more confined trajectories in
anti-PD-L1 treated tumors as compared to the controls. Some T-cells in close
contact to the tumor cells were with rounded, compact cell shape and probing
behaviors. T-cells are GFP+ (green), tumor cells are mCherry+ (red) and collagen
fibers were seen as second harmonic signals (cyan).
Supplementary Video 3 | Intravital imaging of T-cell behavior on Day 21 in a
B78ChOva-mCherry tumor treated with combined anti-CTLA-4 and anti-PD-L1
therapy. An expansion in the numbers of GFP+ T-cells were detected in tumors of
mice treated with combined immune checkpoint inhibitors therapy. High number
of fast-moving T-cells with directional and sustained movement in the tumor
periphery were detected, and numerous T-cells were observed with low motility
and confined movements near tumor cells. T-cells are GFP+ (green), tumor cells
are mCherry+ (red), and collagen fibers were seen as second harmonic
signals (cyan).
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